Expert Opin Investig Drugs 32(5):355359 Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S et al (2022) LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Reliable MD believes in a collaborative approach to healthcare and will collaborate with you to create a weight loss plan that aligns with your goals, discussing the potential benefits and risks of Ozempic
It works by stimulating angiogenesis (the growth of new blood vessels), improving blood flow to injured areas and supporting the migration and proliferation of healing cells (Gwyer et al., 2019)
After the IV, limit sun exposure, skip steam/sauna, and avoid smoking or drinking for at least a day
Explore our training programs built for clients managing GLP-1 therapy alongside structured strength work